BREAST CANCER

FDA prioritizes review of T-DXd for first-line HER2-positive breast cancer treatment, showcasing significant survival benefits in recent studies.

The evERA study reveals promising results for giredestrant in treating advanced ER-positive breast cancer, enhancing progression-free survival for patients.

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPION-Breast01 trial. This is the second of 2 parts from this event.

During a live event, Neil M. Iyengar, MD, discusses NCCN guidelines and NATALEE trial data for using CDK4/6 inhibitors like ribociclib in N0 and N1 breast cancer.

FDA fast tracks GLSI-100 for HER2-positive breast cancer, promising new hope for patients with unmet medical needs. Discover its potential benefits.

Researchers identify IL-6 as a key biomarker predicting resistance to CDK4/6 inhibitors in metastatic breast cancer, highlighting new therapeutic targets.

Experts explore the potential of invasive disease-free survival as a key metric in breast cancer trials, aiming to accelerate treatment approvals.

A groundbreaking study shows trastuzumab pamirtecan significantly improves progression-free survival in HER2-positive breast cancer patients, marking a major oncology advancement.

During a live event, Neil M. Iyengar, MD, discusses how genomic risk scores and menopausal status guide complex adjuvant therapy choices in breast cancer.

Abemaciclib significantly enhances survival rates in high-risk early breast cancer, establishing its role as a standard treatment alongside endocrine therapy.

During a live event, Kit Yu Lu, MD, discussed data on antibody-drug conjugates in HR+, HER2- breast cancer including the TROPiCS-02 trial.

FDA reviews gedatolisib for advanced breast cancer, showing significant progression-free survival improvements in pivotal VIKTORIA-1 trial.

Vepdegestrant emerges as a groundbreaking treatment for ESR1-mutated breast cancer, showing significant improvements in progression-free survival over traditional therapies.

A pivotal trial evaluates patritumab deruxtecan for advanced HR-positive, HER2-negative breast cancer, offering hope for patients after standard therapies.

A novel assay identifies low-risk patients with high-risk ER+/HER2– early breast cancer, potentially sparing them from unnecessary treatment escalation.

A new study reveals personalized treatment strategies for HER2-negative breast cancer, optimizing antibody-drug conjugate sequencing based on tumor characteristics.

The FDA accepts a new drug application for vepdegestrant, a promising oral PROTAC developed by Arvinas and Pfizer, signaling potential breakthroughs in treatment.

ProteinQure's PQ203, a novel peptide drug conjugate, gains FDA fast track designation for advanced triple-negative breast cancer clinical trials in North America.

A groundbreaking trial explores personalized endocrine therapy for early-stage breast cancer, aiming to reduce chemotherapy's side effects and improve patient outcomes.

New clinical trial results reveal gedatolisib significantly improves progression-free survival in advanced HR+/HER2– breast cancer, offering hope for patients.

Atossa Therapeutics advances Z-endoxifen for ER+/HER2- metastatic breast cancer, receiving FDA support for dose optimization and combination therapy strategies.

Atezolizumab enhances long-term outcomes in triple-negative breast cancer, revealing promising insights on ctDNA as a prognostic biomarker.

A novel triple therapy shows promise for advanced triple-negative breast cancer, offering hope for patients with limited treatment options.

Mariam Eskander, MD, explores how food insecurity and geographic barriers hinder breast cancer trial participation, highlighting urgent needs for systemic change.

Patritumab deruxtecan shows promising survival rates and manageable safety in treating leptomeningeal metastatic disease, offering hope for patients with limited options.